UroGen Pharma: Undervalued Chemoablative Disruptor in NMIBC With Blockbuster Potential by 2030

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on URGN stock, giving a Buy rating on April 20.

Ram Selvaraju has given his Buy rating due to a combination of factors tied to ZUSDURI’s clinical profile and commercial prospects. The KOL feedback emphasized ZUSDURI as a disruptive chemoablative option that can spare patients from lengthy, high‑risk TURBT procedures, while its gel-based delivery enables prolonged bladder exposure, strong long‑term response rates, and a favorable safety profile in a broad NMIBC population.

He also views the pricing and market dynamics as highly attractive, with ZUSDURI positioned competitively—even below JELMYTO on cost—while targeting the largest NMIBC subsegment and a sizable, historically underserved patient pool. Combined with the potential to reach blockbuster-level sales by 2030 and only minor adjustments to forward revenue estimates, these elements support Selvaraju’s conviction that UroGen shares remain undervalued, justifying a continued Buy recommendation.

In another report released on April 20, Piper Sandler also maintained a Buy rating on the stock with a $40.00 price target.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of URGN in relation to earlier this year.